Medicine:V451 vaccine
| Vaccine description | |
|---|---|
| Target disease | SARS-CoV-2 |
| Type | Subunit |
| Clinical data | |
| Other names | SARS-CoV-2 Sclamp |
| Routes of administration | Intramuscular |
| Legal status | |
| Legal status |
|
V451 was a COVID-19 vaccine candidate developed by the University of Queensland and the Australian pharmaceutical company CSL Limited. The vaccine candidate used the University of Queensland's molecular clamp technology[1] and the MF59 adjuvant.[2]
Description
V451 is a subunit vaccine. As part of the vaccine's design, researchers added "a fragment of one protein found on the HIV virus"[3] as a "ground-breaking molecular clamp technology".[4]
Terminated trial
The development of the vaccine was cancelled on 11 December 2020 during its Phase I trial, after a number of trial participants were found to give false positive test results for HIV antibodies when they did not in fact have HIV.[5][6] This was due to the HIV virus fragment used as a molecular clamp leading to "a partial antibody response" to HIV. This is an undesirable outcome as it will interfere with future HIV screening tests for affected participants.[7]
Nine days prior to the termination, on 2 December, the first emergency use authorisation had been granted to a COVID-19 vaccine; the Pfizer–BioNTech COVID-19 vaccine in the United Kingdom.[8] Following the termination of V451, vaccine production capacity by CSL Limited was diverted to the Oxford–AstraZeneca COVID-19 vaccine.[9]
See also
- COVID-19 pandemic in Australia
References
- ↑ "UQ-CSL V451 Vaccine" (in en-US). https://www.precisionvaccinations.com/vaccines/uq-csl-v451-vaccine.
- ↑ "Why a COVID-19 vaccine could further imperil deep-sea sharks". National Geographic. 13 November 2020. https://www.nationalgeographic.com/animals/2020/11/why-covid-19-vaccine-further-imperil-deep-sea-sharks/.
- ↑ "How the UQ coronavirus vaccine induced false-positive HIV test results and why scientists were prepared". ABC News. 11 December 2020. https://www.abc.net.au/news/2020-12-11/how-the-uq-covid-19-vaccine-induces-false-positive-hiv-results/12975048.
- ↑ "Australia abandons local Covid vaccine over HIV test concerns". Financial Times. 11 December 2020. https://www.ft.com/content/94228a8f-caa9-41ad-bce2-3f1ae43537cc.(Subscription content?)
- ↑ "Covid: Australian vaccine abandoned over false HIV response" (in en-GB). BBC News. 2020-12-11. https://www.bbc.com/news/world-australia-55269381.
- ↑ Reuters Staff (2020-12-10). "BRIEF-CSL Says Will Not Progress UQ-CSL V451 COVID-19 Vaccine Candidate To Phase 2/3 Clinical Trials" (in en). Reuters. https://www.reuters.com/article/brief-csl-says-will-not-progress-uq-csl-idUSASN000MG6.
- ↑ "Australia ends local COVID vaccine trials due to HIV false positives". Deutsche Welle. 11 December 2020. https://www.dw.com/en/australia-ends-local-covid-vaccine-trials-due-to-hiv-false-positives/a-55900847.
- ↑ "UK medicines regulator gives approval for first UK COVID-19 vaccine". 2 December 2020. https://www.gov.uk/government/news/uk-medicines-regulator-gives-approval-for-first-uk-covid-19-vaccine.
- ↑ "COVID-19 Update" (in en-US). https://www.csl.com/news/2020/covid-19-update.
External links
- Clinical trial number NCT04495933 for "A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults" at ClinicalTrials.gov
 |
